VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. BLO BLOZF (the “Company or Cannabix”), developer of marijuana breath testing devices for law enforcement and the workplace, reports that it will participate in a study in mid-October to develop a supplemental version of its FAIMS technology to detect ∆9-tetrahydrocannabinol (” THC”) and related analytes in human breath in a comprehensive multi-analysis study of subjects under the influence of marijuana in the southern United States. Cannabix participated in two days of testing, held in June and July in two different U.S. cities. The October event will take place at a new location Southern US Study, Cannabix works with toxicologists and law enforcement officials who test subjects under the influence of marijuana. The company’s technology (proprietary breath capture and marijuana detection devices, described below) is used alongside several conventional drug screening methods, including blood and oral fluid sampling. Furthermore, a closed driving test to assess the impairment is planned for the study date in mid-October. Details of the study will be available in due course when the Company is granted disclosure approval.

Data from previous studies show a very consistent correlation of THC levels in head-to-head comparisons between breath samples collected and analyzed with Cannabix hardware and the current standard of whole blood. The Company’s portable Breath Collection Unit (“BCU”, Fig. 1) and newly developed laboratory “MS Breath Sampler” (Fig. 2) are used together to provide a new breakthrough method of drug detection that complements the gold standard mass spectrometry (MS) and greatly simplifies laboratory analysis methods, reducing sample turnaround time (thereby minimizing operating costs) while maintaining sensitive, accurate results.

The company has developed a unique breath capture system capable of…